Compare GENC & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | ADAG |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.2M | 222.2M |
| IPO Year | 1995 | 2020 |
| Metric | GENC | ADAG |
|---|---|---|
| Price | $17.50 | $1.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $21.00 | $9.91 |
| AVG Volume (30 Days) | 32.5K | ★ 196.5K |
| Earning Date | 12-08-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.08 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | $1.78 | N/A |
| Revenue Next Year | $25.68 | $129.59 |
| P/E Ratio | $19.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.22 | $1.50 |
| 52 Week High | $20.19 | $4.85 |
| Indicator | GENC | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 31.30 |
| Support Level | $16.75 | N/A |
| Resistance Level | $18.11 | $3.50 |
| Average True Range (ATR) | 0.55 | 0.26 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 70.15 | 0.94 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.